9,329 results match your criteria American journal of hematology[Journal]


POEMS Syndrome: update on diagnosis, risk-stratification, and management.

Am J Hematol 2019 Apr 22. Epub 2019 Apr 22.

Professor of Medicine and Laboratory Medicine, Mayo Clnic.

Disease Overview: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25495DOI Listing

Prognostic significance of upfront radiation therapy in patients with multiple myeloma.

Am J Hematol 2019 Apr 21. Epub 2019 Apr 21.

Department of Medicine, Brown University, Warren Alpert Medical School, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25492DOI Listing

Bleeding Incidence and Risk Factors among Cancer Patients Treated with Anticoagulation.

Am J Hematol 2019 Apr 21. Epub 2019 Apr 21.

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.

Compared to age-matched controls, cancer patients have increased risk of bleeding when treated with anticoagulation. However, there are little data regarding bleeding as it relates to anticoagulant choice and other risk factors. We evaluated the 6-month incidence of bleeding among patients treated with anticoagulation and bleeding risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25494DOI Listing

Detection of Extranodal and Spleen Involvement by FDG-PET Imaging Predicts Adverse Survival in Untreated Follicular Lymphoma.

Am J Hematol 2019 Apr 21. Epub 2019 Apr 21.

Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Predicting early clinical failure in patients with untreated follicular lymphoma (FL) is important but difficult. This study aimed to determine the incidence and patterns of extranodal (EN) and spleen disease using PET/CT, and assess their utility in predicting early clinical failure. PET/CT images from 613 cases of untreated FL (2003 - 2016) were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25493DOI Listing

Pleomorphic mantle cell lymphoma mimicking diffuse large B cell lymphoma in peripheral blood and bone marrow.

Am J Hematol 2019 Apr 20. Epub 2019 Apr 20.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25491DOI Listing
April 2019
2 Reads

Suboptimal Response Rates to Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia; a Single Institutional Study of 121 Patients.

Am J Hematol 2019 Apr 9. Epub 2019 Apr 9.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Hypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group) MDS (myelodysplastic syndrome) and MDS/myeloproliferative neoplasm (MPN) overlap syndrome response criteria, in 121 CMML patients treated with Azacitidine (AZA, n=56) and Decitabine (DAC, n=65). The overall response rates were 41% by the IWG MDS (AZA- 45%, DAC-39%) and 56% by the IWG MDS/MPN (AZA-56%, DAC-58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria; without significant differences in response rates between proliferative and dysplastic CMML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25488DOI Listing
April 2019
1 Read

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.

Am J Hematol 2019 Apr 8. Epub 2019 Apr 8.

Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneity in the clinical course of MCL-indolent vs aggressive-is further delineated by a correlation with the mutational status of the variable region of immunoglobulin heavy chain, methylation status, and SOX-11 expression. Cyclin-D1 negative MCL, in situ MCL neoplasia, and impact of the karyotype on prognosis are distinguished. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25487DOI Listing
April 2019
6 Reads

DDX41 Mutations in Myeloid Neoplasms are Associated with Male Gender, TP53 Mutations and High-Risk Disease.

Am J Hematol 2019 Apr 8. Epub 2019 Apr 8.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Myeloid neoplasms with germline DDX41 mutations have been incorporated into the 2017 WHO classification. Limited studies describing the clinicopathologic features and mutation profile are available. We searched for myeloid neoplasms with a DDX41 gene mutation tested by an 81-gene next-generation sequencing panel (Illumina MiSeq) over a 7-month period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25486DOI Listing
April 2019
3.798 Impact Factor

The D-dimer assay.

Am J Hematol 2019 Apr 4. Epub 2019 Apr 4.

Division of Hematology and Hematologic Malignancies, University of Utah Health Sciences Center, Salt Lake City, Utah.

D-dimer is an indirect marker of fibrinolysis and fibrin turnover; this molecule exhibits unique properties as a biological marker of hemostatic abnormalities as well as an indicator of intravascular thrombosis. D-dimer is a soluble fibrin degradation product that results from the systematic degradation of vascular thrombi through the fibrinolytic mechanism. Because of this, the D-dimer serves as a valuable marker of activation of coagulation and fibrinolysis in a number of clinical scenarios. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25482
Publisher Site
http://dx.doi.org/10.1002/ajh.25482DOI Listing
April 2019
1 Read

Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango.

Am J Hematol 2019 Apr 3. Epub 2019 Apr 3.

Department of Pharmacy, University of Patras School of Health Sciences, Patras, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25485DOI Listing

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Am J Hematol 2019 Apr 3. Epub 2019 Apr 3.

University of Colorado School of Medicine, Aurora, CO, USA.

Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy, and identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25484DOI Listing
April 2019
1 Read

Immune neutropenia mediated by micafungin.

Am J Hematol 2019 Apr 3. Epub 2019 Apr 3.

Division of Hematology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25483
Publisher Site
http://dx.doi.org/10.1002/ajh.25483DOI Listing
April 2019
7 Reads

Second-Line Treatments in Children with Immune Thrombocytopenia: Effect on Platelet Count and Patient-Centered Outcomes.

Am J Hematol 2019 Apr 3. Epub 2019 Apr 3.

Texas Children's Hematology Center, Baylor College of Medicine, Houston, TX.

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely observed, treatments are often needed for various reasons, including to decrease bleeding or improve health related quality of life (HRQoL). There are a number of available second-line treatments, including rituximab, thrombopoietin-receptor agonists, oral immunosuppressive agents, and splenectomy, but data comparing treatment outcomes are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25479DOI Listing
April 2019
4 Reads

MYH9-related disease mutations cause abnormal red blood cell morphology through increased myosin-actin binding at the membrane.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.

MYH9-related disease (MYH9-RD) is a rare, autosomal dominant disorder caused by mutations in MYH9, the gene encoding the actin-activated motor protein non-muscle myosin IIA (NMIIA). MYH9-RD patients suffer from bleeding syndromes, progressive kidney disease, deafness, and/or cataracts, but the impact of MYH9 mutations on other NMIIA-expressing tissues remains unknown. In human red blood cells (RBCs), NMIIA assembles into bipolar filaments and binds to actin filaments (F-actin) in the spectrin-F-actin membrane skeleton to control RBC biconcave disk shape and deformability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25472DOI Listing
March 2019
1 Read

The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Division Hematology, Oncology, and Bone Marrow Transplantation, University of Iowa, Iowa City, Iowa.

Indolent B-cell lymphomas other than follicular lymphoma account for up to 10% of all B-cell neoplasms. While they typically follow a slowly progressive course, some patients experience rapid progression and early mortality. Prognostic scoring systems have not been adopted, hindering the ability of clinicians or researchers to predict outcomes, or risk-stratify patients during clinical trials. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25473
Publisher Site
http://dx.doi.org/10.1002/ajh.25473DOI Listing
March 2019
2 Reads

Low-dose vemurafenib in hairy cell leukemia patients with active infection.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25474DOI Listing
March 2019
1 Read

Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan.

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25475
Publisher Site
http://dx.doi.org/10.1002/ajh.25475DOI Listing
March 2019
22 Reads

Sickle cell microvascular paradox-oxygen supply-demand mismatch.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Division of Cardiology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

We have previously demonstrated that sickle cell disease (SCD) patients maintain normal global systemic and cerebral oxygen delivery by increasing cardiac output. However, ischemic end-organ injury remains common suggesting that tissue oxygen delivery may be impaired by microvascular dysregulation or damage. To test this hypothesis, we performed fingertip laser Doppler flowmetry measurements at the base of the nailbed and regional oxygen saturation (rSO ) on the dorsal surface of the same hand. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25476
Publisher Site
http://dx.doi.org/10.1002/ajh.25476DOI Listing
March 2019
3 Reads

Plasmacytoma presenting as jugular foramen tumor in a young woman with multiple myeloma.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Department of Medicine, Harvard Medical School, Boston, Massachusetts.

A 29-year-old African American woman with a history of iron-deficiency anemia presented with one-year of ear fullness and hearing loss. She also endorsed right unilateral pulsatile tinnitus and loss of sense of taste on the right side. She initially failed to improve on oral antibiotics and was referred to otolaryngology when symptoms worsened over the next several months. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25477
Publisher Site
http://dx.doi.org/10.1002/ajh.25477DOI Listing
March 2019
7 Reads

Normal Saline Bolus Use in Pediatric Emergency Departments is Associated with Worse Pain Control in Children with Sickle Cell Anemia and Vaso-occlusive Pain.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

Vaso-occlusive pain events (VOE) are the leading cause of emergency department (ED) visits in sickle cell anemia (SCA). This study assessed the variability in use of intravenous fluids (IVFs) and the association of normal saline bolus (NSB) on pain and other clinical outcomes in children with SCA presenting to pediatric emergency departments (PED) with VOE. Four-hundred charts of children age 3-21 years with SCA/VOE receiving parenteral opioids at 20 high-volume PEDs were evaluated in a retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25471DOI Listing
March 2019
3.798 Impact Factor

Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.

Am J Hematol 2019 Mar 22. Epub 2019 Mar 22.

Division of Haematology, Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China.

The present study aimed to define a subtype of complex/monosomal karyotype (CK/MK) acute myeloid leukemia (AML) by its distinct clinical features, p53 signaling and responses to p53 targeting agents. Ninety-eight young adults (range: 21-60 years; median: 49 years) with CK/MK AML were studied. They received standard induction, consolidation and allogeneic hematopoietic stem cell transplantation from siblings or matched unrelated donors if available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25469DOI Listing
March 2019
2 Reads

Curative potential of hematopoietic stem cell transplantation for advanced psoriasis.

Am J Hematol 2019 Mar 22. Epub 2019 Mar 22.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25470DOI Listing
March 2019
2 Reads

Importance of and strategies for achieving gender equity in hematology.

Am J Hematol 2019 Mar 22. Epub 2019 Mar 22.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25468
Publisher Site
http://dx.doi.org/10.1002/ajh.25468DOI Listing
March 2019
3 Reads

Effects of rifaximin on circulating aged neutrophils in sickle cell disease.

Am J Hematol 2019 Mar 22. Epub 2019 Mar 22.

Division of Hematology and Hemostasis, New York Medical College, Valhalla, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25467DOI Listing
March 2019
1 Read

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.

Am J Hematol 2019 Mar 21. Epub 2019 Mar 21.

Division of Hematologic Malignancies and and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Single agents have demonstrated activity in relapsed and refractory (R/R) peripheral T-cell lymphoma (PTCL). Their benefit relative to combination chemotherapy remains undefined. Patients with histologically confirmed PTCL were enrolled in the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) registry. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25463
Publisher Site
http://dx.doi.org/10.1002/ajh.25463DOI Listing
March 2019
4 Reads

Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura.

Am J Hematol 2019 Mar 21. Epub 2019 Mar 21.

Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25466DOI Listing
March 2019
3 Reads

High frequency of false-positive results of aPTT-based lupus anticoagulant tests in patients receiving argatroban.

Am J Hematol 2019 Mar 18. Epub 2019 Mar 18.

James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25465DOI Listing

Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.

Am J Hematol 2019 Mar 18. Epub 2019 Mar 18.

Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, Nebraska.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25464DOI Listing
March 2019
1 Read

Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.

Am J Hematol 2019 May 23;94(S1):S10-S17. Epub 2019 Mar 23.

Cell Therapy and Transplant Program, Division of Hematology-Oncology, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Studies of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) have demonstrated the potential to produce deep remissions-and possibly cures-in some patients with heavily pretreated, high-risk, relapsed, and refractory disease. Unfortunately, most clinical trials of CAR T cells in CLL report complete responses only in the minority of patients, although recent studies have begun to elucidate the factors most predictive of response. These studies have suggested strategies for optimizing CAR T-cell fitness as well as the pre-existing host immune response, approaches that will likely lead to improvements in the efficacy of CAR T cells in CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25457DOI Listing
May 2019
2 Reads

HemoTypeSC Demonstrates >99% Field Accuracy in a Sickle Cell Disease Screening Initiative in Children of Southeastern Uganda.

Am J Hematol 2019 Mar 11. Epub 2019 Mar 11.

Department of Radiology, Mulago National Referral Hospital, Kampala, Uganda.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25458DOI Listing
March 2019
3 Reads

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Am J Hematol 2019 Mar 11. Epub 2019 Mar 11.

Department of Vascular Medicine, CNRS / TIMC-IMAG UMR 5525/Themas and F-CRIN InnoVTE Network, Grenoble, Auvergne-Rhône-Alpes, France.

The risk of venous thromboembolism (VTE) is higher in myeloma patients receiving immunomodulatory compounds. A VTE prophylaxis using low-molecular-weight heparin or aspirin is therefore proposed. Apixaban is an oral direct anti-Xa. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25459
Publisher Site
http://dx.doi.org/10.1002/ajh.25459DOI Listing
March 2019
8 Reads

Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

Am J Hematol 2019 May;94(5):604-616

Perelman Center for Advanced Medicine, University of Pennsylvania, Division, Philadelphia, Pennsylvania.

Disease Overview: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by clinical features, cell of origin (COO), molecular features, and most recently, frequently recurring mutations.

Diagnosis: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan-B-cell antigens, such as CD20 and CD79a. COO is determined by immunohistochemical stains, while molecular features such as double-hit or triple-hit disease are determined by fluorescent in situ hybridization analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25460DOI Listing
May 2019
4 Reads

Elevated urinary 3-indoxyl sulfate in sickle cell disease.

Am J Hematol 2019 Mar 9. Epub 2019 Mar 9.

Division of Hematology and Hemostasis, New York Medical College, Valhalla, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25456DOI Listing
March 2019
1 Read

Spontaneous healing of avascular necrosis of the femoral head in sickle cell disease.

Am J Hematol 2019 Mar 5. Epub 2019 Mar 5.

Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25453DOI Listing
March 2019
3 Reads

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Am J Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities such as angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. Herein, to improve the current molecular classification between AITL and PTCL-NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their molecular configuration and integrated them with genomic data of recurrently mutated genes (RHOA , TET2, IDH2 , and DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included in the series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25450DOI Listing
March 2019
3 Reads

Splenic rupture in cytomegalovirus infection.

Am J Hematol 2019 Feb 25. Epub 2019 Feb 25.

Department of Haematology, St Mary's Hospital and Centre for Haematology, St Mary's Hospital Campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25449DOI Listing
February 2019
2 Reads

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Am J Hematol 2019 May 13;94(5):563-574. Epub 2019 Mar 13.

Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25448DOI Listing
May 2019
4 Reads
3.798 Impact Factor

Toxicities of CD19 CAR-T cell immunotherapy.

Am J Hematol 2019 May 6;94(S1):S42-S49. Epub 2019 Mar 6.

Clinical Research Division and Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.

CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has demonstrated impressive results in B-cell malignancies, and CAR-T cell therapies targeting other antigens are in development for other cancers. Cytokine release syndrome (CRS) and neurotoxicity can be life-threatening in a subset of patients. The severity of CRS and neurotoxicity can be impacted by the disease burden, lymphodepletion regimen, and CAR-T cell dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25445DOI Listing
May 2019
1 Read

Chimeric antigen receptor T cells for acute lymphoblastic leukemia.

Authors:
Noelle V Frey

Am J Hematol 2019 May 22;94(S1):S24-S27. Epub 2019 Mar 22.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Chimeric antigen receptor (CAR) modified T cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL). With regulatory approval for tisagenlecleucel and many other agents under active investigation, the use of CAR T cells for ALL continues to expand. While some remissions from anti-CD19 CAR T cells are durable without a consolidative allogeneic stem cell transplantation, CD19 positive and negative relapses remain a significant concern fueling investigations into the biology of CAR T cell persistence and the development of CARTs that target more than 1 antigen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25442DOI Listing

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.

Am J Hematol 2019 May 8;94(5):575-584. Epub 2019 Mar 8.

Laboratory of Clinical Chemistry & Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

In sickle cell disease (SCD), sickle hemoglobin (HbS) polymerizes upon deoxygenation, resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced deformability, leading to vaso-occlusive crises and chronic hemolytic anemia. To date, there are no reliable laboratory parameters or assays capable of predicting disease severity or monitoring treatment effects. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25443
Publisher Site
http://dx.doi.org/10.1002/ajh.25443DOI Listing
May 2019
15 Reads